J&J's Tremfya posts forecast-topping quarter (Firstwordpharma Press Release) - Oct 13, 2026 - "Johnson & Johnson said Tuesday that sales of Tremfya continued to grow in the third quarter — jumping 68.3% over the prior year to $2.4 billion and above analyst expectations of $2.2 billion...In the three-month period, sales of Stelara plunged 54.4% to $716 million, with Simponi and Remicade both down 17.3%, to $568 million and $394 million, respectively."
Sales • Ankylosing Spondylitis • Crohn's disease • Plaque Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis
|